Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous CAL101 in idiopathic pulmonary fibrosis
NL-OMON60997Phase 2Active, not recruiting
- Sponsor
- Calluna Pharma
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing CAL101 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Started Sep 2025; status: active, not recruiting.
02
Drugs
idelalisib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON60997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60997.